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Abstract
Multidrug resistance protein Pdr5p is a yeast ATP-binding cassette (ABC) transporter in the plasma membrane. It confers
multidrug resistance by active efflux of intracellular drugs. However, the highly polymorphic Pdr5p from clinical strain
YJM789 loses its ability to expel azole and cyclohexmide. To investigate the role of amino acid changes in this functional
change, PDR5 chimeras were constructed by segmental replacement of homologous BY4741 PDR5 fragments. Functions of
PDR5 chimeras were evaluated by fluconazole and cycloheximide resistance assays. Their expression, ATPase activity, and
efflux efficiency for other substrates were also analyzed. Using multiple lines of evidence, we show that an alanine-to-
methionine mutation at position 1352 located in the predicted short intracellular loop 4 significantly contributes to the
observed transport deficiency. The degree of impairment is likely correlated to the size of the mutant residue.
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Introduction
ATP-binding cassette (ABC) transporters are integral mem-
brane proteins that carry diverse substrates across plasma
membrane [1,2]. Active extrusion of xenobiotics mediated by
ABC transporters is one of the most common resistance
mechanisms developed by microorganisms. [3,4,5]. As the most
abundant ABC transporter in Saccharomyces cerevisiae, Pdr5p plays a
major role in cellular detoxification via efflux of a wide variety of
drugs and substrates in an ATP-dependent manner [6,7,8,9].
Predicted topology of Pdr5p shows that it carries two highly
hydrophobic transmembrane domains (TMDs) and two nucleotide
binding domains (NBDs) [10,11]. In a functional Pdr5p trans-
porter, several amino acid residues of the TMDs determine
substrate specificity [12], whereas some other amino acid residues
of the NBDs are responsible for nucleotide binding and/or
hydrolysis, then couple the liberated energy to conformational
changes at the TMDs, which allow the translocation of drug
substrates across plasma membrane barrier [13,14]. Residues in
NBDs may also selectively affect substrate selection [15]. The
mechanism for how Pdr5p recognizes and transports a large
number of structurally distinct substrates still remains unclear [16].
Previous reports have described many site-directed mutations in
NBDs or TMDs of Pdr5p [11,12,13,15,17,18,19], leading to
elucidation of the roles of single amino acid in the overall function
of the protein. These studies emphasized on alterations affecting
ATP hydrolysis and/or binding, as well as transport of substrates
through the membrane. Pathogenic strain YJM789 was derived
from a clinical S. cerevisiae isolate (YJM128) collected from the lung
of an AIDS patient [20]. PDR5 in YJM789 strain contains 274
nucleotide differences (5.3% divergence) resulting in 80 amino
acid changes from PDR5 in the lab strain BY4741 (hereafter
referred to as BPDR5), whereas at the whole genome level the
nucleotide difference between these two strains is only 0.43% [21].
Interestingly, most of the amino acid differences occur in two
TMDs [22]. Our earlier work presented evidence that the drug-
efflux function of Pdr5p in YJM789 strain is impaired by its
dramatic sequence divergence although YJM789 Pdr5p localized
to plasma membrane similarly to BY4741 Pdr5p. Further study
illustrated that the sequence divergence in the TMD2 segment
leads to fluconazole and cycloheximide hypersensitivity of
YJM789, which contains a part of the predicted C-terminal
NBD and the whole C- terminal TMD coding regions of PDR5 in
YJM789 strain (hereafter referred to as YPDR5) [22].
In this study, the mutated sites in YPDR5 TMD2 segment that
impair Pdr5p drug-efflux function were traced by the segment
replacement method. The results show an A1352M mutation in
the predicted intracellular loop 4 (ICL4) [11,23,24,25] can cause
severe decrease of drug export ability.
Results
Mutation sites in block S2A and S2B are critical for Pdr5p-
mediated drug resistance
Previous studies found that Pdr5p in YJM789 strain cannot
export its drug substrates such as cyclohexmide and fluconazole
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29520efficiently [22,26]. In this study, YPDR5 and BPDR5 were
overexpressed from high-copy plasmids. As shown in Fig. 1A,
cells expressing BPDR5 were able to grow as well as wild type
BY4741 on media containing 3 mg/mL fluconazole or 75 ng/mL
cyclohexmide, while cells expressing YPDR5 were phenotypically
similar to the pdr5 null mutant G1. It shows that the dramatic
sequence divergence in YPDR5 disrupts its drug-efflux function
under overexpression background. By exchanging of NBD-TMD
coding regions in BPDR5 with their counterparts in YPDR5, PDR5
chimeras PDR5-1 and PDR5-2 were constructed. Drug suscepti-
bility analysis revealed that cells expressing PDR5-1 had similar
drug resistance patterns as cells expressing BPDR5, while cells
expressing PDR5-2 was as same as pdr5 null mutant. This result
suggests that sequence divergence in the C-terminal NBD-TMD
region of YPDR5 can abrogate the Pdr5p-mediated drug
resistance.
To identify which amino acid residues are important for the
efflux function of Pdr5p, additional PDR5 chimeras PDR5-S1 and
Figure 1. Identification of residues important for Pdr5p function and distribution of mutations in YJM789 Pdr5p. (A) Segmental
replacement of BY4741 PDR5 and drug resistance profiles of pdr5D S. cerevisiae cells expressing wild type and chimeric PDR5s by spot assay. Various
regions of BY4741 PDR5 are segmentally replaced by corresponding segments from YPDR5. Segments from BY4741 and YJM789 PDR5 are shown as
white and grey rectangles, respectively. The unique Bsp I, Mlu I, Bsp1407 I restriction sites, which were used to construct PDR5 chimeras are marked.
Five-fold serial dilutions of pdr5D mutant carrying different PDR5 constructs were spotted on SD/-Ura media in the absence and the presence of 3 mg/
mL fluconazole or 75 ng/mL cycloheximide. Plates were incubated for 72 hours at 30uC. (B) The topological model is based on the molecular
modeling study of Pdr5p [11]. Two-dimensional schematic cartoon of Pdr5p shows the 12 predicted membrane spanning helices (white spheres) and
two NBDs (blue spheres). The green boxed areas indicate the TMDs. Divergent residues between BY4741 and YJM789 are shown as red, purple and
dark blue spheres, respectively. Ala 1352 is indicated by black arrow.
doi:10.1371/journal.pone.0029520.g001
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sequence of PDR5-2 into two segments S1 and S2. After
transforming PDR5-S1 or PDR5-S2 overexpression plasmid into
the fluconazole-sensitive pdr5 null mutant G1, their drug sensitivity
to fluconazole was tested. As shown in Fig. 1A, cells expressing
PDR5-S1 presented the similar drug resistant phenotypes as cells
expressing BPDR5, whereas cells expressing PDR5-S2 were highly
susceptible to fluconazole. Hence, sequence divergence in the
segment S2 from YPDR5 can cause reduction in Pdr5p-mediated
fluconazole resistance.
In order to narrow down the critical regions for Pdr5p function,
segment S2 from YPDR5 was subdivided into 3 blocks (S2A, S2B
and S2C) to replace their homologous regions in BPDR5 and the
resulted PDR5 chimeras were designated as PDR5-S2A, PDR5-S2B
and PDR5-S2C, respectively. Comparison of drug resistance
phenotypes shows that the replacement of block S2C did not
affect the Pdr5p-mediated fluconazole efflux, while PDR5-S2A and
PDR5-S2B resulted in hypersusceptibility to fluconazole and
cyclohexmide as compared to BPRD5 (Fig. 1A). Sequence analysis
shows that PDR5-S2A and PDR5-S2B possess 5 (Fig. 1B, purple
spheres) and 4 amino acid mutations (Fig. 1B, dark blue spheres),
respectively. These changed residues could disturb Pdr5p–
mediated drug efflux.
A1352M mutant strain is sensitive to fluconazole and
cyclohexmide
In order to investigate which mutations in the S2A and S2B
regions can alter the capacity of Pdr5p to confer drug resistance, as
well as whether there are any additive or synergistic effects in
mutation combinations, nine mutants expressing variants of PDR5
including V1338I, L1344F, V1345A, N1349I, A1352M, S1360T,
M1365I, S1368C and C1370S were constructed (See Table 1).
The drug resistance patterns of all above Pdr5p mutants were
indistinguishable from WT except A1352M mutant (Fig. 2A),
which was hypersensitive to fluconazole and cyclohexmide. A
similar phenotype was observed when relative fluconazole (Fig. 2B)
and cyclohexmide (Fig. 2 C) resistance of A1352M mutant,
BPDR5 and pdr5D mutant was determined in liquid media. Taken
together, these results demonstrate that one single amino acid
substitution of alanine 1352 with methionine is sufficient to impair
Pdr5p function. In addition, the fact that all four single mutations
separated from PDR5-S2B (S1360T, M1365I, S1368C and
C1370S) could functionally complement the pdr5D mutant
suggests the existence of synergistic effects among these mutations
(Fig. 2A).
A1352M mutant strain is transport-deficient
Furthermore, we analyzed the capability of A1352M mutant to
transport rhodamine 6G (R6G) in vivo. Null mutants of pdr5 were
known to cause increased accumulation of R6G. As shown in
Fig. 3A, A1352M mutant was more sensitive to R6G that BPDR5,
the flow cytometry results (Fig. 3B) show that intracellular
accumulation of R6G was much higher in A1352M mutant than
that in cells expressing BPDR5. It demonstrates that transport
capabilities of A1352M mutant are compromised. As a result, the
observation that A1352M mutant conferred lower fluconazole and
cycloheximide resistance than BPDR5 resulted from transport
deficiency of Pdr5p.
Mutational analysis of A1352 in Pdr5p
We further substituted the alanine residue in position 1352 with
glycine (A1352G), serine (A1352S), proline (A1352P), valine
(A1352V), and leucine (A1352L). The consequence of single
residue changes in position 1352 to modulate Pdr5p mediated
cycloheximide resistance was examined by spot assay after
transformation of G1 with the corresponding overexpression
plasmids. In order to compare the growth patterns of the mutants
in different concentrations of cycloheximide, drug sensitivity
analysis based on quantitative measurements of optical densities
of liquid cell cultures was performed simultaneously as described
in the method. As shown in Fig. 4, the capacities of A1352 mutants
in conferring cycloheximide resistance were all slightly lower than
that of BPDR5. The discrepancies of drug resistance for distinct
mutations at position 1352 demonstrate that the size of residue at
this position can affect the Pdr5p-mediated drug export.
Mutations in A1352 elicit alteration in Pdr5p function
To ascertain that the observed differences in cycloheximide
resistance are due to alterations in Pdr5p function rather than poor
Pdr5p expression level or mislocalization of Pdr5p variants, plasma
membranes from A1352 mutants were prepared and analyzed by
SDS-PAGE. The presence of a specific band corresponded to
Pdr5p in membranes from mutant variants of PDR5 but was
absent in membranes from pdr5D indicates that BY4741 Pdr5p
and its A1352 mutant proteins are properly expressed and
localized to plasma membrane with comparable levels (Fig. 5).
This was further confirmed by immunoblotting with antibodies
against Pdr5p (Fig. 5).
Pdr5p-specific ATPase activity is unaffected by mutations
in A1352
Energy released from ATP hydrolysis drives the substrate
transport by Pdr5p. In order to examine whether the observed
changes in cycloheximide resistance was accompanied by
alterations in Pdr5p-specific ATPase activities, plasma membranes
isolated from mutants carrying Pdr5p variants were used to
determine their ATPase activities. It is apparent from Fig. 6 that,
compared to plasma membranes from the cells expressing BPDR5,
there was no significant difference in plasma membrane ATPase
activity of cells expressing mutant PDR5, the plasma membranes
from pdr5 null mutant exhibit considerably reduced ATPase
activity. Therefore, mutations at A1352 do not seem to interfere
with Pdr5p-specific ATPase activity.
Discussion
S. cerevisiae Pdr5p belongs to the ABC super-family of primary
transporters which directly couples ATP hydrolysis to substrate
transport. It not only expels azoles and its derivatives but also
extrudes a variety of structurally unrelated compounds [1,26]. To
understand the structure-function relationships of Pdr5p, we took
advantage of the highly polymorphic Pdr5p from clinical strain
YJM789 that have lost its ability to export azoles. By exchanging
segments of BY4741 PDR5 with their counterparts from YJM789
PDR5, we found that A1352M substitution could cause consider-
able reduction in Pdr5p mediated drug resistance.
As shown in Fig. 1B, Pdr5p shares a common architecture with
other ABC transporters, which contains two TMDs and each of
the two is comprised of six membrane-spanning helices connected
by three extracellular loops (ECLs) and two intracellular loops
(ICLs). Recent molecular modeling study on Pdr5p [11] shows
that A1352 (The purple sphere indicated by arrow in Fig. 1B) is
located in the ICL4 which connects TMH 10 and TMH 11 in
TMD2. It is widely accepted that interactions between the
membrane-bound domains and cytosolic domains of ABC
transporters are critical for their transport capabilities. The high-
resolution structure of Staphylococcus aureus Sav1866 suggests that
A Mutation in ICL4 Affects Pdr5p Efflux Activity
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glycoprotein by chemical cross-linking suggests that ICL4 within
TMD2 forms an interface with NBD1 [28]. Studies of CFTR
(Cystic Fibrosis Transmembrane Regulator) mutants demonstrate
a tertiary interaction between the surface of NBD1 and ICL4 in
TMD2 [29]. ICL4-NBD1 interaction in Yor1p (another ABC
transporter in S. cerevisea) has been defined by chemical cross-
linking experiments. [30]. All above studies supported an interface
with a trans arrangement in which ICL4 within TMD2 interacts
with the NBD of the opposite half of the molecule.
Despite their distinct molecular architecture, it could be inferred
from the predicted topological models that ICL4 in Pdr5p
corresponds to ICL4 in above mentioned ABC transporters. It is
possible that the ICL4 of Pdr5p is involved in interdomain cross-
talk. Reduction of drug resistance in A1352M mutant may
attributable to the alterations of ICL4 that uncouple interdomain
cross-talk. However, substitution of A1352 with more rigid amino
acid residue proline does not show significant reduction in the
drug resistance and the mutant possess the same level of ATPase
activity as BPDR5 (data not shown). Genetic and biochemical
studies from Pdr5p strongly suggest that the Pdr5p signaling
interface is in the cis rather than the trans configuration,
interactions between the TMH2 and NBD1 occur via the ICL1
[13,14].Therefore, it is unlikely that the reduced resistance to drug
substrates in the A1352M mutant was a consequence of
uncoupling of interdomain cross-talk.
The reported crystal structures of Sav1866 [27] and mouse P-
glycoprotein [31] suggest that the transmembrane helices in TMDs
form a substrate-binding pocket. Modeling of Pdr5p shows that
Ala1352 is pointing toward the predicted substrate-binding pocket
[11]. It is more likely that the transport-deficiency of A1352M
mutant is caused by the increased length of residue which results in
affecting accessibility of binding pocket to intracellular substrates.
We also increased the residue size at position 1352 by substituting
Table 1. Strains and plasmids.
Strains or plasmids Relevant characteristics Reference
Strains
S. cerevisiae BY4741 MATa his3 leu2 met15 ura3 Yeast Knock-out (YKO) deletion collection
S. cerevisiae YJM789 MATa hoD::hisG gal2 lys2 [35]
S. cerevisiae G1 MATa his3 leu2 met15 ura3 pdr5::loxP This study
E. coli DH5a SupE44, DlacU169 (w80 lacZDM15), hsdR17, recA1, endA1,




pSH47 URA3, Cre EUROSCARF
YEplac195 URA3
pTA2 TOYOBO
YEplac195-BPDR5 URA3, expressing BY4741 PDR5 This study
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(A1352L). Western blot result showed that the expression levels of
all above A1352 mutants were similar to that of BPDR5. The drug
resistance assays also support that substitutions of Ala residue with
larger residues tend to have more severe impact on Pdr5p, resulting
in increased sensitivity to cycloheximide.
Previous work shows that A1352 and the negatively charged
E1353 in ICL4 are very conserved by aligning PDR5 with other
fungal ABC transporters, and E1353 is predicted to located at the
edge of substrate-binding pocket [11].When positively charged Lys
(K) and uncharged Gln (Q) were used to substitute the similar-size
E1353, only E1353K mutant shows significant decrease in drug
Figure 2. Drug resistance profiles of cells expressing PDR5 variants. (A) Nine mutated sites distributed throughout blocks S2A and S2B were
separated by site-directed mutagenesis and fluconazole sensitivities of mutant variants were determined by spot assay. Cells were grown overnight
and reinoculated to OD600=0.1, then 4 mL of five-fold serial dilutions were spotted onto drug free or drug containing (3 mg/mL fluconazole or 75 ng/
mL cycloheximide) SD/-Ura plates. The plates were incubated at 30uC for 72 hours. (B) Resistance of BPDR5 (X), pdr5D (m) and A1352 (&) mutants to
increasing concentrations of fluconazole. Cells from overnight cultures were inoculated to OD600=0.1. Growth was estimated on the basis of OD600
and plotted as percentage growth, where the growth in drug free media was taken to be 100%. The mean values of three independent experiments
are plotted and the error bars represent the S.D. (C) Growth of BPDR5 (X), pdr5D (m) and A1352 (&) mutants was compared as described in B, except
that the experiment was performed in the presence of increasing concentrations of cycloheximide.
doi:10.1371/journal.pone.0029520.g002
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in neutralizing positively charged substrates such as rhodamine 6G.
It requires further investigation to understand whether the
importance comes from its role in substrate recognition.
Interestingly, the A1352 was identified to be under positive
selection by branch-site model (P v.1, posterior probability of
NEB was 0.98, and BEB was 0.93). Although this significance is
not extremely high, the fast evolution of A1352 indicates that this
amino acid is responsible for the changing of Pdr5p function in
drug transport.
In summary, mutation of A1352 in ICL4 could disturb Pdr5p
mediated drug resistance pattern without affecting its ATPase
activity, expression level or protein localization. It hints that the
ICL4 of Pdr5p may play an important role in substrates
recognition and export. While, there is no report about ICL4
function in Pdr5p, our observation of the functional importance of
A1352 might encourage further studies on this region.
Materials and Methods
Strains, media and growth conditions
S. cerevisiae BY4741 (MAT a, his3D, leu2D, met15D, ura3D) and
YJM789 (MAT a,h o D::hisG, gal2D, lys2D) were used for PDR5
cloning. pdr5 null mutant G1 (MAT a, his3D, leu2D, met15D, ura3D,
pdr5D::loxP) was constructed as previously described [32]. Esche-
richia coli strain DH5a was used for plasmid manipulation.
E. coli cells were grown in LB medium. Yeast strains were grown
on standard rich YPD medium. SD uracil-deficient medium was
used to select ura3 auxotrophic derivatives of transformants. Solid
media were supplemented with 2% agar.
Figure 3. Pdr5p-mediated efflux of rhodamine 6G in BPDR5 and mutant cells. (A) Rhodamine 6 G resistance of BPDR5 (%), pdr5D (m) and
A1352 (&) mutants were compared in liquid culture as described in materials and methods. Growth in the absence of R6G was served as control.
Growth at each concentration of R6G is shown as (% control). The mean values of three independent experiments are plotted and the error bars
represent the S.D. (B) The transport capabilities of BPDR5, pdr5D and A1352M were compared with flow cytometry. The histogram derived from the
CellQuest software depicts fluorescence intensities for BPDR5 (black), pdr5D (red) and A1352M (blue).
doi:10.1371/journal.pone.0029520.g003
Figure 4. Drug resistance profiles of pdr5D S. cerevisiae cells expressing wild type and A1352 mutant variants of PDR5 on agar plates
and in liquid culture. (A) Drug sensitivity of A1352 mutant variants determined by spot assay. Serial dilutions of BPDR5 cells, pdr5D and A1352
mutant variants were spotted on SD/-Ura agar plates in the absence (left panel) and the presence (right panel) of 75 ng/mL cycloheximide,
respectively. The plates were incubated at 30uC for 72 hours. (B) Quantitative analysis of drug resistance mediated by Pdr5p mutants. Cells carrying
empty plasmid or overexpressing BPDR5, A1352 mutant variants as indicated, were subjected to analysis in liquid culture as described in materials
and methods. OD600 values at 12 h were analyzed. Growth in drug free cultures of each strain was served as control. Normalized growth rates are
shown as the means 6 standard deviations (error bars) for three independent experiments at each concentration of cycloheximide.
doi:10.1371/journal.pone.0029520.g004
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Stock solutions of fluconazole (FLC) and Rhodamine 6G (R6G)
were prepared in 20% dimethyl sulfoxide at final concentrations of
5 mg/mL and 10 mM. Cycloheximide (CYH) solution (1 mg/mL)
was purchased from Sigma-Aldrich.
Plasmid construction and transformation
Construction of plasmids YEplac195-BPDR5, YEplac195-
YPDR5, YEplac195-PDR5-1 and YEplac195-PDR5-2 has been
described previously [22]. An 1851 bp segment was amplified by
PCR from YEplac195-YPDR5 with forward primer #01 and
reverse primer #02. The PCR product was digested with BstP I
and Mlu I and ligated to YEplac195-BPDR5 cut accordingly
producing PDR5-S1. PDR5-S2 was similarly generated using
forward primer #03, reverse primer #04 and Mlu I–Sph Ia s
restriction enzymes. The PCR product of primer pair #03 and
#04 was also ligated into the pTA2 vector to obtain pTA-S2 for
further modification.
For substituting blocks S2C in YEplac195-BPDR5 by its
counterpart from YEplac195-YPDR5, YEplac195-BPDR5 was cut
with restriction enzymes Pst I-Bsp1407 I, the resulted restriction
fragment of 209 bp was recovered and used to replace its
counterpart sequence in pTA-S2, yielding intermediate plasmids
pTA-S2C; pTA-S2C was then digested with single restriction site
enzymes Mlu I and Sph I and ligated to YEplac195-BPDR5 cut
accordingly, creating PDR5-S2C.
PDR5-S2A and PDR5-S2B were constructed as follows. Inverse
PCR amplification was performed using PAGE-grade PCR
primers #05 and #06 which containing the desired non-
synonymous base pair substitutions indicated by uppercase letters
and pTA-S2C plasmid DNA isolated from E. coli DH5a as
template. After Dpn I digestion of the methylated template
plasmid, self-ligation of PCR product was conducted in a reaction
mixture which includes both T4 Polynucleotide Kinase
(TOYOBO) and T4 DNA ligase (Fermentas). The resulted
plasmid was labeled pTA-S2A. The same procedure was applied
to construct pTA-S2B using primer pair #07 and #08.
Substitutions of nucleotides introduced by primers were confirmed
by DNA sequencing. Mlu I–Sph I fragments from pTA-S2A and
pTA-S2B were used to replace the homologous fragments in
YEplac195-BPDR5 generating PDR5-S2B and PDR5-S2A, respec-
tively. The sequences of primers used for plasmid construction are
listed in Table 2.
Yeast transformations were performed by LiAc/SS carrier
DNA/PEG high efficiency transformation protocol [33].
Site-directed mutagenesis of PDR5
The Mlu I–Sph I DNA fragment from YEplac195-BPDR5 was
used to replace the homologous fragment in pTA-S2 creating
pTA-mu. pTA-mu was then served as the template for site-
directed mutagenesis to create PDR5 mutants. Site directed
mutagenesis was performed using the Quick Change kit
(Stratagene). Mutations were introduced into YEplac195-BPDR5
Figure 5. Membrane localization of Pdr5p and its mutant
variants. Isolated plasma membranes (15 mg/lane) were electropho-
resed on an SDS–8% polyacrylamide gel and visualized with Coomassie
blue (top panel). Pdr5p (middle panel) and Pma1p (bottom panel) were
immunodetected with specific antibodies as described in the materials
and methods section. Filled arrowheads indicate Pdr5p and open
arrowheads indicate Pma1p. Coomassie blue stained SDS-PAGE gel
(upper panel) and western blot (lower panel) of the same strains are
shown.
doi:10.1371/journal.pone.0029520.g005
Figure 6. The effect of A1352M mutation on the ATPase
activity of Pdr5p. Plasma membrane preparations (0.25 mg/well) from
BPDR5 (dark), pdr5D (gray) and A1352M (white) were incubated in 25 mL
reaction buffer containing 300 mM Mes-Tris (pH 7.4), 4 mM ATP, 5 mM
MgCl2, 0.2 mMammonium molybdate, 50 mM KNO3, and 10 mM NaN3
at 30uC for 20 min. The oligomycin-sensitive activity was determined as
the difference in the ATPase activity in the presence or absence of
20 mg/mL oligomycin. The figure shows the means of three indepen-
dent experiments, and the error bars represent standard error.
doi:10.1371/journal.pone.0029520.g006











Underlined: modified or newly generated endonuclease restriction sites.
doi:10.1371/journal.pone.0029520.t002
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by exchanging the Mlu I–Sph I fragments in plasmids.
All PCR amplifications were performed with the KOD-Plus
system (TOYOBO). After every cloning, the entire chimeric
construct was sequenced by using the Big Dye Terminator Cycle
sequencing kit and an ABI 3730xl DNA analyzer to ensure that
the construct remained in-frame and no unwanted mutations had
been introduced.
Drug sensitivity analysis
Each transformed yeast strain to be tested was grown in SD/-
Ura medium to late exponential phase. Then cells were washed
and subsequently resuspended in sterile water to an OD600 of 0.1.
For spot assay, aliquots (4 mL) of 5-fold serial dilutions were
spotted onto SD/-Ura plates lacking or containing drugs to be
tested. Plates were incubated at 30uC for 72 hours. For
quantitative measurements of optical densities of liquid cell
cultures, cultures were treated with different concentrations of
cycloheximide. 150 mL normalized cultures were seeded onto
NUNC 96 well optical bottom plates (in triplicate) and covered
with adhesive plate sealers in Power Wave XS microplate
spectrophotometer (BioTek) with constant shaking at 30uC.
OD600s for each well were recorded using Gen5 software every
15 minutes for 24 hours.
Preparation of purified membrane vesicles and
immunoblots
Plasma membranes were prepared as described previously [15].
The protein concentration was determined by Bradford assay.
Equivalent amounts of protein were separated by SDS-PAGE with
8% gel. Immunoblotting was done using standard methods. Pdr5p
specific goat polyclonal antibody yN-18 and Pma1 specific
antibody yN-20 were from Santa Cruz Biotechnology. HRP
labeled donkey anti-goat polyclonal antibody was from Beyotime
Co. Proteins were visualized using the ECL chemiluminescence
detection system (BeyoECL Plus).
ATPase activity assays
Pdr5p-associated OM-sensitive ATPase activity of the isolated
plasma membrane fractions was measured as described previously
[15]. Absorbance data were collected using a Power Wave XS
microplate spectrophotometer equipped with Gen5 software
(BioTek).
Rhodamine 6G transport assay
Transport of rhodamine 6G was determined as described
previously [13]. The data were analyzed with a CellQuest
program. Fluorescence was expressed in arbitrary units.
Detecting positive selection
10 PDR5 gene sequences of different S. cerevisiae strains were
selected from website (http://www.sanger.ac.uk/research/projects/
genomeinformatics/sgrp.html). Pdr5p sequences were aligned using
ClustalW with the default parameter settings, and were then
reversely translated into nucleotide sequences using MEGA4 [34].
The evolutionary rate of amino acid sites was detected by using the
branch-site model of positive selection, as implemented in codeml
program in PAML package [27].
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